Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thein, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thein, S.
Haematologica, Vol 90, Issue 5, 649-660
Copyright © 2005 by Ferrata Storti Foundation


Journal Article

Genetic modifiers of beta-thalassemia

SL Thein

Department of Haematological Medicine, Guy's, King's & St. Thomas' School of Medicine King's College London, Denmark Hill Campus, Bessemer Road, London SE5 9PJ, UK. sl.thein@kcl.ac.uk

As the defective genes for more and more genetic disorders become unravelled, it is clear that patients with apparently identical genotypes can have many different clinical conditions even in simple monogenic disorders. Beta thalassemia occurs when there is a deficiency in the synthesis of beta globin chains. The clinical manifestations of beta thalassemia are extremely diverse, spanning a broad spectrum from severe anemia and transfusion-dependency to the asymptomatic state of thalassemia trait. The remarkable phenotypic diversity of the beta thalassemias is prototypical of how a wide spectrum of disease severity can be generated in single gene disorders. The most reliable and predictive factor of disease phenotype is the nature of the mutation at the beta globin locus itself. However, relating phenotype to genotype is complicated by the complex interaction of the environment and other genetic factors at the secondary and tertiary levels, some implicated from family studies, and others, as yet unidentified. This article reviews the clinical and hematologic diversity encountered in beta thalassemia with an overview of the modifier genes that moderate their disease expression.


This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
A Mosca, R Paleari, G Ivaldi, R Galanello, and P C Giordano
The role of haemoglobin A2 testing in the diagnosis of thalassaemias and related haemoglobinopathies
J. Clin. Pathol., January 1, 2009; 62(1): 13 - 17.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
H. P. J. Voon, H. Wardan, and J. Vadolas
siRNA-mediated reduction of {alpha}-globin results in phenotypic improvements in {beta}-thalassemic cells
Haematologica, August 1, 2008; 93(8): 1238 - 1242.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. Sleegers, N. Brouwers, S. Maurer-Stroh, M. A. van Es, P. V. Damme, P.W.J. van Vught, J. van der Zee, S. Serneels, T. D. Pooter, M. Van den Broeck, et al.
Progranulin genetic variability contributes to amyotrophic lateral sclerosis
Neurology, July 22, 2008; 71(4): 253 - 259.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.